Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
NCT ID: NCT06208007
Last Updated: 2024-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
150 participants
OBSERVATIONAL
2024-02-23
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Energetic Abnormalities in Heart Failure With Preserved Ejection Fraction
NCT00628082
CMR Exercise Stress Testing in HFpEF
NCT03260621
Non-invasive Evaluation of Myocardial Stiffness by Elastography
NCT02537041
Predicting Heart Failure Outcomes With Biomarkers and Imaging
NCT07332520
Effect of Aterial Stiffness on Myocardial Work in Patients With Hypertension
NCT04573257
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 60 years
* Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)
* Diabetes mellitus Type I or II
* Atrial fibrillation
* Chronic kidney disease (GFR \< 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g)
* BMI ≥ 30 kg/m2
* NYHA ≥ II
* E/e' \> 8
Exclusion Criteria
* Significant valve disease (Grade III or higher)
* History of interventional or surgical valve repair
* Regional wall motion abnormalities
* Respiratory diseases as a known cause for dyspnea
* Atrial flutter or fibrillation during examination
* Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy
* History of heart transplantation
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Center Goettingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexander Schulz
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsmedizin Göttingen
Göttingen, Lower Saxony, Germany
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9/12/23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.